Physician profile
Scott Williams
NPI 1407816341
$606.63
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $125 · 2021: $47.39 · 2022: $91.64 · 2023: $122 · 2024: $24.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $129.41 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $116.20 | 2019-2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $46.89 | 2023 | Givlaari |
| Mallinckrodt Enterprises LLC | $40.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.50 | 2019-2020 | |
| Boston Scientific Corporation | $24.59 | 2024 | |
| Mallinckrodt Hospital Products INC. | $24.10 | 2022 | |
| Leadiant Biosciences, INC. | $23.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.56 | 2021 | |
| Recordati_rare_diseases_inc. | $22.78 | 2023 | Cystadrops |
| Ani Pharmaceuticals, INC. | $20.44 | 2022 | |
| Horizon Therapeutics Plc | $19.86 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $19.78 | 2023 | Imcivree |
| Novo Nordisk INC | $16.74 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amicus Therapeutics, INC. | $14.96 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.